Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.accessioned | 2021-09-04T13:03:43Z | - |
dc.date.available | 2021-09-04T13:03:43Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92602 | - |
dc.description.abstract | We compared the efficacy of high-dose cytarabine alone to that of intermediate-dose cytarabine combined with anthracyclines as consolidation therapy. Patients enrolled in the Korea University acute myeloid leukemia (AML) registry received remission induction chemotherapy with the same standard induction regimen (idarubicin and cytarabine 3 + 7). Postremission therapy was performed for three or four cycles according to one of the following regimens: high-dose cytarabine (3 g/m(2)) or combination of intermediate-dose cytarabine (1 g/m(2)) with anthracyclines (idarubicin or mitoxantrone). Among the 443 AML patients enrolled in the registry, 145 patients received consolidation chemotherapy. The median overall survival (OS) and relapse-free survival (RFS) in the high-dose cytarabine group were significantly longer than those in the anthracycline combination group (OS, not reached vs. 16.6 months, p = 0.045; RFS, 38.6 months vs. 11.0 months, p = 0.011). The median duration of neutropenia was longer in the anthracycline combination group than in the high-dose cytarabine group (8 vs. 10 days, p = 0.001). This study suggests that high-dose cytarabine consolidation may produce superior outcomes than combination treatment with intermediate-dose cytarabine and anthracyclines and that the addition of anthracyclines during AML consolidation has limited value as compared to cytarabine intensification. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | ACUTE MYELOCYTIC-LEUKEMIA | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | RESISTANCE | - |
dc.subject | ADULTS | - |
dc.subject | DAUNORUBICIN | - |
dc.subject | AML | - |
dc.title | Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.contributor.affiliatedAuthor | Lee, Se Ryeon | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.contributor.affiliatedAuthor | Sung, Hwa Jung | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.contributor.affiliatedAuthor | Kim, Byung Soo | - |
dc.identifier.doi | 10.1007/s00277-015-2389-9 | - |
dc.identifier.scopusid | 2-s2.0-84938749457 | - |
dc.identifier.wosid | 000359013700007 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.94, no.9, pp.1485 - 1492 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 94 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1485 | - |
dc.citation.endPage | 1492 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | ACUTE MYELOCYTIC-LEUKEMIA | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | DAUNORUBICIN | - |
dc.subject.keywordPlus | AML | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | Consolidation chemotherapy | - |
dc.subject.keywordAuthor | High-dose cytarabine | - |
dc.subject.keywordAuthor | Anthracyclines | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.